An Interventional Study of Infigratinib in Children With Hypochondroplasia
NCT06873035
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
ENROLLING_BY_INVITATION
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypochondroplasia
Interventions
DRUG:
infigratinib 0.128 mg/kg/day
DRUG:
infigratinib 0.25 mg/kg/day
Sponsor
QED Therapeutics, a BridgeBio company